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Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute
inflammatory vesiculobullous reactions of the skin and mucous membranes. Cold medicines including
non-steroidal anti-inflammatory drugs andmulti-ingredient coldmedications are reported to be important
inciting drugs. Recently, we reported that cold medicine related SJS/TEN (CM-SJS/TEN) with severe
mucosal involvement including severe ocular surface complications (SOC) is associated with HLA-A*02:06
and HLA-B*44:03 in the Japanese. In this study, to determine whether HLA-B*44:03 is a common risk
factor for CM-SJS/TEN with SOC in different ethnic groups we used samples from Indian, Brazilian, and
Korean patients with CM-SJS/TEN with SOC, and investigated the association between CM-SJS/TEN with
SOC and HLA-B*44:03 and/or HLA-A*02:06. We found that HLA-B*44:03 was significantly associated
with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population, and that HLA-
A*02:06 might be weakly associated in the Korean- but not the Indian and Brazilian population.
S
tevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN) with spots, are
acute inflammatory vesiculobullous reactions of the skin and mucous membranes such as the ocular
surface, oral cavity, and genitals. They are rare but often associated with inciting drugs and/or infectious
agents1–3.
The association between human leukocyte antigen (HLA) genotypes and drug-induced severe cutaneous
adverse reactions (SCARs) including SJS/TEN has been reported. There was a strong association between
HLA-B*58:01 and SCARs, including SJS/TEN and the drug-induced hypersensitivity syndrome (DIHS),
induced by the uric acid lowering drug allopurinol. This association was observed in Han Chinese-4,
Caucasian-5, and Japanese patients6, suggesting that different ethnic groups share the same risk factor(s)
for allopurinol-induced SCARs. HLA-B*15:02 exhibited a very strong association with carbamazepine-
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induced SJS/TEN in Taiwanese Han Chinese patients7 and HLA-
A*31:01 was strongly associated with carbamazepine-induced
SCARs including SJS/TEN in Japanese-8 and European patients9.
We recently reported that cold medicine-related SJS/TEN with
severe mucosal involvement including severe ocular surface com-
plications (SOC) is associated with HLA-A*02:06 and HLA-
B*44:03 in Japanese patients10.
The ophthalmologists Mondino et al.11 and the dermatologists
Roujeau et al.12,13 reported that HLA-B12 (HLA-Bw44) was signifi-
cantly increased in Caucasian SJS patients many of whom developed
SJS/TEN after taking non-steroidal anti-inflammatory drugs
(NSAIDs). HLA-B12 is primarily coded by HLA-B*44:02 or HLA-
B*44:03 (http://www.allelefrequencies.net/). The significant asso-
ciation between HLA-B12 and SJS/TEN in Caucasian patients may
be attributable to their genetic background.
To determine whether HLA-B*44:03 is a common risk factor for
CM-SJS/TEN with SOC in different ethnic groups we used samples
from Indian, Brazilian, and Korean patients with CM-SJS/TEN with
SOC, and investigated the association between CM-SJS/TEN with
SOC and HLA-B*44:03 and/or HLA-A*02:06.
Methods
Our study was approved by the institutional review boards of the participating
institutions. All experimental procedures were conducted in accordance with the
principles of the Helsinki Declaration. The purpose of the research and the experi-
mental protocols were explained to all participants, and their prior written informed
consent was obtained.
Patients and controls. Ophthalmologists diagnosed SJS/TEN based on a confirmed
history of acute-onset high fever, serious mucocutaneous illness with skin eruptions,
and involvement of at least two mucosal sites including the ocular surface1,14,15. They
defined patients with SOC as those who manifested a pseudomembrane and an
epithelial defect on the ocular surface in the acute stage, and as patients with ocular
sequelae such as dry eye, trichiasis, symblepharon, and conjunctival invasion into the
cornea in the chronic stage.
As in our previous study, we focused on SJS/TEN with SOC suspected of having
been induced by cold medicines such as multi-ingredient cold medications and
NSAIDs. As we found earlier that the genetic predisposition might be different
between SJS/TEN with and without severe mucosal involvement including SOC10 we
focused on patients from different ethnic groups who presented with SJS/TEN with
SOC.
Samples from Indian patients with CM-SJS/TEN were collected at the LV Prasad
Eye Institute (n 5 20; 12 males, 8 females; age range 7 to 63 years; median age 27.1 6
13.4 (SD) years). Their age at onset ranged from 3 to 42 years (median age at onset,
19.2 6 12.2 (SD) years; in 8 patients the age at onset was unknown). The drugs
administered to these patients and the HLA type (A and B) of patients with CM-SJS/
TEN with SOC are shown in Supplemental Table 1. The specific drug(s) were not
known in all patients. Healthy volunteers (n 5 55; 29 males, 26 females; median age
36.0 6 11.6 years) served as the Indian controls.
Samples from Brazilian patients with CM-SJS/TEN were collected at the Federal
University of Sao Paulo (n5 39, 15males, 24 females; age range 13 to 69 years; median
age, 37.1 6 15.9 years; age range at onset, 3 to 69 years; median age at onset, 24.0 6
17.2 years). The drugs administered, the ethnicity, and the HLA type (A and B) of
these CM-SJS/TEN patients with SOC are shown in Supplemental Table 2. Healthy
volunteers (n 5 134; 55 males, 79 females; median age 41.2 6 12.8 years) were the
Brazilian controls (ethnicity: pardo, n 5 66; white, n 5 62; black, n 5 4, Indian plus
white, n 5 2).
Samples from Korean patients with CM-SJS/TEN were collected at the Seoul
National University College of Medicine, Chonnam National University, Yonsei
University, and the Catholic University of Korea. There were 31 patients (12males, 19
females) ranging in age from 4 to 71 years (median age 33.76 19.0 years). Their age at
SJS/TENonset ranged from3 to 63 years (median age at onset, 23.06 16.1 years). The
drugs used and the HLA type (A and B) of these patients with SOC are presented in
Supplemental Table 3. The specific drug(s) were not known in all patients. Healthy
volunteers (n 5 90; 35 males, 55 females; median age 31.7 6 7.9 years) were the
Korean controls.
Samples from Indian subjects were obtained by extracting DNA from whole
peripheral blood with the phenol chloroform method. For Brazilian samples, DNA
was extracted from whole peripheral blood using the PAX gene blood DNA kit
(Qiagen, Hilden, Germany) or from saliva using Oragene DNA (Kyodou
International, Kanagawa, Japan). To obtain the samples from Korean subjects, DNA
was extracted from whole peripheral blood using the PAXgene Blood DNA kit
(Qiagen).
HLA genotyping. For the analysis of HLA-A and HLA-B we performed polymerase
chain reaction (PCR) assays followed by hybridization with sequence-specific
oligonucleotide probes using commercial bead-based typing kits (Wakunaga,T
ab
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Hiroshima, Japan). Briefly, the target DNA was PCR-amplified with biotinylated
primers specifically designed for amplified exons 2 and 3 of HLA-A, and -B genes.
Then the PCR amplicon was denatured and hybridized to complementary
oligonucleotide probes (72 probes for HLA-A, 93 probes for HLA-B) immobilized on
fluorescent-coded microsphere beads. At the same time, the biotinylated PCR
product was labeled with phycoerythrin-conjugated streptavidin and immediately
examined with Luminex 100 (Luminex, Austin, TX, USA). Genotype determination
and data analysis were performed automatically using the WAKFLOW typing
software (Wakunaga, Hiroshima, Japan) according to the manufacturer’s
instructions.
Statistical analysis. We compared the carrier frequency and gene frequency of
individual HLA alleles in the patients and controls with the x2-test (Pearson) (JMP
version 11 software; SAS Institute Japan Ltd., Tokyo, Japan).
Results
Strong association between HLA-B*44:03 and CM-SJS/TEN with
SOC in Indian patients. We genotyped HLA-A and HLA-B in
samples from Indian subjects (20 CM-SJS/TEN with SOC patients
and 55 controls). Although the number of Indian subjects was small,
we found a strong and significant association between their CM-SJS/
TEN with SOC and HLA-B*44:03 (carrier frequency: p 5 1.07 3
1025, odds ratio (OR) 5 12.25, gene frequency: p 5 9.37 3 1028, OR
5 10.88) but not HLA-A*0206 (Table 1).
Significant association between HLA-B*44:03 and CM-SJS/TEN
with SOC in Brazilian patients. Next we genotyped HLA-A and
HLA-B in samples from Brazilian subjects (39 CM-SJS/TEN with
SOC patients and 134 controls). Although the number of Brazilian
subjects was small we found a significant association between
Brazilian patients with CM-SJS/TEN with SOC and HLA-B*44:03
(carrier frequency: p 5 0.0239, OR 5 2.74, gene frequency: p 5
0.0121, OR 5 2.77) but not HLA-A*0206 which is absent in the
Brazilian population (Table 1). Interestingly, in Caucasians in the
Brazilian samples (Brazilian Caucasian CM-SJS/TEN with SOC
patients: n 5 15, Brazilian Caucasian controls: n 5 62), the
association with HLA-B*44:03 was stronger (carrier frequency:
p 5 0.0037, OR 5 6.22, gene frequency: p 5 0.0011, OR 5 5.99).
Association betweenHLA-A*02:06 and Korean patients with CM-
SJS/TEN with SOC. We also genotyped HLA-A and HLA-B in
samples from Koreans (31 patients with CM-SJS/TEN with SOC
and 90 controls). Although the number of Korean patients was
small we found a significant association between patients with
CM-SJS/TEN with SOC and HLA-A*0206 (carrier frequency: p 5
0.0362, OR 5 3.00, gene frequency: p 5 0.0263, OR 5 2.46) but not
HLA-B*44:03 (Table 1).
Discussion
We previously reported that in the Japanese, CM-SJS/TEN with
severe mucosal involvement including SOC was associated with
HLA-A*02:06 and HLA-B*44:0310. In the present study we investi-
gated whether the association with these alleles is shared by other
ethnic groups. We found that HLA-B*44:03 was strongly associated
with CM-SJS/TEN with SOC in the Indian population which is gen-
etically close to European populations16 and significantly associated
in the Brazilian population which is comprised of individuals with
different ethnic backgrounds. There was no association between
HLA-B*44:03 andCM-SJS/TENwith SOC in the Korean population.
HLA-A*02:06was weakly associated in the Korean population which
is genetically close to the Japanese, but not in the Indian and Brazilian
population.
HLA-B12 (HLA-Bw44) was significantly increased in Caucasian
SJS patients many of whom developed SJS/TEN after taking NS-
AIDs11–13. Because HLA-B12 is primarily coded by HLA-B*44:02 or
HLA-B*44:03 (http://www.allelefrequencies.net/), the significant
association of HLA-B12 with SJS/TEN in Caucasian patients may
be attributable to the association with the HLA-B*44:03 genotype.
We also found that in Brazilian Caucasian patients with CM-SJS/
TEN with SOC, the significant association with HLA-B*44:03 was
stronger than in the entire study population of Brazilians with CM-
SJS/TEN with SOC. To determine whether HLA-B*44:03 is a com-
monmarker for CM-SJS/TEN with SOC in Caucasian, HLA analysis
of European patients with CM-SJS/TEN with SOC is needed.
AlthoughHLA-A*02:06was strongly associated with the Japanese
CM-SJS/TEN with SOC, and the Korean and Japanese population is
genetically close16, in Korean patients CM-SJS/TEN with SOC was
not strongly associated with HLA-A*02:06. To determine whether
HLA-A*02:06 is a common marker for CM-SJS/TEN with SOC in
East Asian populations further investigations using a larger number
of samples are needed.
We also performed a meta-analysis by adding our previously-
reported samples10. We used Cochran-Mantel-Haenszel statistics
and found that both HLA-A*02:06 and HLA-B*44:03 are signifi-
cantly associated with CM-SJS/TEN with SOC (Supplemental
Table 4).
SCARs including SJS/TEN and DIHS induced by allopurinol were
commonly and strongly associated withHLA-B* 58:01 in patients of
different ethnic backgrounds including Han Chinese-4, Caucasian-5,
and Japanese patients6. This observation suggests that different eth-
nic groups share the same risk factor(s) for allopurinol-induced
SCARs.
With respect to carbamazepine-induced SJS/TEN, different HLA
alleles are associated. HLA-B*15:02 is associated in Taiwanese Han
Chinese patients7 and HLA-A*31:01 in Japanese-8 and European
patients9.
In CM-SJS/TEN with SOC, the associated alleles we identified are
HLA-A*02:06 in Japanese and Korean patients and HLA-B*44:03 in
Indian-, Brazilian-, and Japanese patients. Studies are underway to
determine whether other HLA alleles are associated with CM-SJS/
TEN with SOC in other populations.
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